Upfront payment for continued clinical development and commercialization of Bylvay®
Sagard to receive a mid-single digit average royalty rate on Bylvay sales
No liens against Bylvay intellectual property
Right to buy out Sagard’s investment at any time
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.